glp-1 r PDB-101: Molecule of the Month: Receptor Agonists Effects of Replacing a Central
Description
In the coming weeks, Novo Nordisk is expected to release fresh Phase III data for its next-generation weight loss treatment CagriSema, which analysts say could be the next big thing in the obesity space
JAMA Network Open , 2025
and its all connected
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
doi: 10.1056/NEJMoa0806359 5 ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSet al
Semaglutide is the active ingredient used in Ozempic
